GSK-2881078
Shop GSK-2881078 on KimeraChems · code GUIDE (10% off)Definition
GSK-2881078 is an investigational selective androgen receptor modulator (SARM) studied for its potential to promote anabolic signaling in muscle and bone while aiming to reduce the broader androgenic profile associated with traditional androgens. In research contexts, it is primarily explored in models of lean-mass preservation, physical-function endpoints, and catabolic states in which androgen-receptor signaling is a key experimental variable. Because SARMs are nonsteroidal androgen-receptor ligands, GSK-2881078 is often discussed as a research tool for isolating androgen-receptor-mediated effects with greater tissue selectivity than testosterone-based paradigms.
Available Formats
- 1 gram powder
- Dry-fill capsules (5 mg per capsule, 60-count / 300 mg total)
- 30 mL liquid solution (10 mg per mL / 300 mg total)
Mechanism of Action
Research suggests GSK-2881078 may: Because androgen-receptor modulation alters endocrine feedback, observed outcomes depend heavily on baseline hormonal status, biological sex, dose selection, and duration of exposure.
- Bind to and selectively activate the androgen receptor
- Promote anabolic gene transcription associated with muscle-protein balance
- Support lean-mass maintenance or accrual in catabolic or detrained models, depending on study design
- Influence bone-related androgen-receptor signaling pathways in certain paradigms
- Suppress endogenous gonadotropin signaling in a dose-dependent manner through androgen-mediated negative feedback
Areas of Investigation
GSK-2881078 is commonly studied in
- Lean-mass-preservation research
- Sarcopenia- and frailty-related models using functional endpoints
- Cachexia and muscle-wasting paradigms in which anabolic resistance is present
- Dose-response studies comparing anabolic outcomes with endocrine-suppression markers
- Comparative studies involving other SARMs or androgen-based control compounds
Safety Profile
Reported observations include
- Suppression of endogenous testosterone-related signaling markers through negative feedback
- Lipid-profile changes, often involving reduced HDL cholesterol in androgen-receptor agonist models
- Headache or gastrointestinal discomfort
- Acne, oily skin, or hair-related changes in androgen-sensitive contexts
- Potential elevations in liver-enzyme biomarkers, treated as a conservative monitoring consideration in some study designs
- Changes in mood, sleep quality, or irritability in stimulation-sensitive models
Interaction Notes
GSK-2881078 is often explored alongside variables that help interpret androgen-receptor-mediated outcomes
For educational purposes only. Not for human consumption.